For: | Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. World J Hepatol 2018; 10(10): 639-644 [PMID: 30386457 DOI: 10.4254/wjh.v10.i10.639] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v10/i10/639.htm |
Number | Citing Articles |
1 |
Laura Bainy Rodrigues de Freitas, Larisse Longo, Deivid Santos, Ivana Grivicich, Mário Reis Álvares-da-Silva. Hepatocellular carcinoma staging systems: Hong Kong liver cancer <i>vs</i> Barcelona clinic liver cancer in a Western population. World Journal of Hepatology 2019; 11(9): 678-688 doi: 10.4254/wjh.v11.i9.678
|
2 |
Xinhua Zou, Wenzhe Fan, Miao Xue, Jiaping Li. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Management and Research 2021; : 4013 doi: 10.2147/CMAR.S304591
|
3 |
Jean-Michel Pawlotsky, Christian B. Ramers, John F. Dillon, Jordan J. Feld, Jeffrey V. Lazarus. Simplification of Care for Chronic Hepatitis C Virus Infection. Seminars in Liver Disease 2020; 40(04): 392 doi: 10.1055/s-0040-1713657
|
4 |
Andrea Bregenzer, Cornelia Krismer, Stefanie Wendel, Patrik Roser, Christoph A. Fux. HCV elimination in a Swiss opioid agonist therapy programme – a cohort study. Swiss Medical Weekly 2022; 152(4950): 40009 doi: 10.57187/smw.2022.40009
|
5 |
Dmitry V. Garbuzenko. Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infection. Medical Journal of the Russian Federation 2021; 27(4): 373 doi: 10.17816/0869-2106-2021-27-4-373-384
|